GenScript Biotech, a China biopharma CDMO, has broken ground to build the GenScript-Legend Biotech Commercial Manufacturing Center in Zhenjiang, China. The facility will specialize in manufacturing plasmids and viruses for cell and gene therapies along with monoclonal antibodies. It will be capable of manufacturing both Phase III and commercial levels of production. Legend Biotech, which partnered its early-stage CAR-T therapy with Janssen Pharma in a package that included a $350 million upfront payment, is a subsidiary of GenScript. Legend is building a cell/gene therapy facility in the US as well.
Source: China Biotoday
